UPDATE - UBS Initiates Coverage on Human Genome (HGSI) with a Neutral; See Stock Range-Bound as GSK Hovers
Tweet
Share
E-mailGet Alerts HGSI Hot Sheet
Price: $14.24 --0%
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
3 Buy, 17 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UPDATE - UBS initiates coverage on Human Genome (Nasdaq: HGSI) with a Neutral. PT $8.
Analyst, Matthew Harrison, said, "We believe Benlysta, HGS’ biologic for lupus, can penetrate a minority share (10-15%) of the SLE market and achieve ~$1B in 2020E sales. We remain below consensus (though not Street low) through 2015 as we see a slow ramp continuing and downside risk to the stock. However, we are Neutral as we believe Benlysta is worth ~$7 to GSK without terminal value. Thus, the current stock price is getting to a level where valuation might be too interesting for GlaxoSmithKline (NYSE: GSK) to ignore."
To see more ratings on HGSI, Click Here
Analyst, Matthew Harrison, said, "We believe Benlysta, HGS’ biologic for lupus, can penetrate a minority share (10-15%) of the SLE market and achieve ~$1B in 2020E sales. We remain below consensus (though not Street low) through 2015 as we see a slow ramp continuing and downside risk to the stock. However, we are Neutral as we believe Benlysta is worth ~$7 to GSK without terminal value. Thus, the current stock price is getting to a level where valuation might be too interesting for GlaxoSmithKline (NYSE: GSK) to ignore."
To see more ratings on HGSI, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform
- CoStar Group acquires Zonda for $800M, adding new home data
Create E-mail Alert Related Categories
Mergers and Acquisitions, New Coverage, RumorsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
